自体免疫疾病相关的事业合作·授权交易 (2016～2024年)

本报告提供自体免疫疾病的治疗药开发相关近来 (2016～2024年) 的事业合作·授权合约的交易趋势相关分析，彙整整体交易形成数量的转变，及财务方面 (付款条件) 的倾向，主要企业的交易形成的动向，契约条件的倾向，各适应症 (治疗标的) 的倾向等调查，近几年主要的联盟交易内容等详细资讯，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 自体免疫疾病相关的交易形成的倾向

• 简介
• 自体免疫疾病相关的交易形成:长期的倾向
• 自体免疫疾病相关的交易形成:各交易类型
• 自体免疫疾病相关的交易形成:各业界
• 自体免疫疾病相关的交易形成:各开发阶段
• 自体免疫疾病相关的交易形成:各技术种类

第3章 自体免疫疾病相关的事业联盟:财务方面的条件

• 简介
• 自体免疫疾病相关的事业联盟被明确指示的财政的条件
• 自体免疫疾病相关的事业联盟:交易总额
• 自体免疫疾病相关的事业联盟:预付款金
• 自体免疫疾病相关的事业联盟:阶段性付款
• 自体免疫疾病相关的事业联盟:使用费率

第4章 与自体免疫疾病相关的主要交易处交易

• 简介
• 自体免疫疾病相关的联盟最活跃的企业
• 自体免疫疾病相关最活跃的企业一览
• 自体免疫疾病相关的主要的交易:契约各金额

第5章 自体免疫疾病的契约文件名录

• 简介
• 是自体免疫疾病相关的事业联盟交易:契约文章阅览可能交易的情况

第6章 自体免疫疾病相关的交易形成:治疗标的

• 简介
• 自体免疫疾病相关的交易形成:治疗标的
• 交易一览
• 自体免疫疾病相关的交易一览，企业名 (ABC顺序，2016～2024年)
• 自体免疫疾病相关的交易一览，各技术种类 (2016～2024年)
• 交易的种类定义
• Biopharma Research Ltd. 相关资料
• 目前联盟
• 目前契约
• Current 来自Partnering的最近报告标题

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 882 autoimmune deals from 2016 to 2024.

The report includes coverage of the following autoimmune diseases:

• Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
• The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
• Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
• Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
• The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
• In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse autoimmune collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

• Trends in autoimmune dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of autoimmune deal records covering pharmaceutical and biotechnology
• The leading autoimmune deals by value
• Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z 2016 to 2024
• Deal Directory - Autoimmune deals by technology type 2016 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016